Topiramate


Literature identifierStudy typeTest dosageEffective dosageEndocrine-mediated endpointsSystems-level perturbations
PMID:38580201IVR3.1 mg 3.1 mgDecreased progesterone levelsReproductive endocrine-mediated perturbations
IVR3.1 mg 3.1 mgDecreased 17-OH-progesterone levelsReproductive endocrine-mediated perturbations
IVR3.1 mg 3.1 mgIncreased androstenedione levelsReproductive endocrine-mediated perturbations
IVR3.1 mg 3.1 mgIncrease in cortisol levelsNeurological endocrine-mediated perturbations
IVR3.1 mg 3.1 mgDecrease in cortisol levelsNeurological endocrine-mediated perturbations
IVR3.1 mg 3.1 mgIncreased 5-alpha-dihydrotestosterone levelsReproductive endocrine-mediated perturbations
IVR3.1 mg 3.1 mgIncreased progestagens levelsReproductive endocrine-mediated perturbations
PMID:38705260IVR41 mg/kg/day 41 mg/kg/dayAlterations in endometrial morphologyReproductive endocrine-mediated perturbations
IVR41 mg/kg/day 41 mg/kg/dayIncreased ovarian weightsReproductive endocrine-mediated perturbations
IVR41 mg/kg/day 41 mg/kg/dayAffects ovarian follicles populationReproductive endocrine-mediated perturbations
IVR41 mg/kg/day 41 mg/kg/dayIncrease in uterine weightsReproductive endocrine-mediated perturbations

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.